The stock may see modest positive sentiment on the enrollment milestone, but the real catalyst is the Q1 2027 data readout. Traders should monitor for any interim data updates or regulatory feedback that could shift the timeline. The long wait until data limits near-term upside.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $17.99entry
- T+1 · 6mo ago +2.33%α +1.94% · $18.41
- T+5 · 5mo ago −1.78%α +2.04% · $17.67
- T+20 · 5mo ago +28.24%α +29.24% · $23.07
- T+60 · 3mo ago +45.02%α +42.53% · $26.09
Price Chart
How similar events traded
Executive Summary
Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial for z-basivarsen in DM1, with topline data expected in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027. This is a key clinical milestone for a company with no approved products, but the stock impact will depend on the actual data readout over a year away.
Key Facts
- Registrational expansion cohort of ACHIEVE trial fully enrolled with 71 participants
- Topline data from the cohort expected in Q1 2027
- Potential BLA submission for U.S. Accelerated Approval planned for Q3 2027
- Potential U.S. launch of z-basivarsen expected in H1 2028 if FDA grants Priority Review
- Z-basivarsen has Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA
- DM1 affects ~40,000 people in the U.S. and ~55,000 in the EU; no approved disease-modifying treatments exist
- Confirmatory Phase 3 HARMONIA trial is ongoing
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue
Risk Factors
- Topline data may fail to meet efficacy or safety endpoints, derailing approval prospects
- Regulatory pathway for Accelerated Approval is uncertain and subject to FDA discretion
- Competing therapies for DM1 could emerge before z-basivarsen reaches market
- Cash burn from ongoing trials without revenue may require future dilutive financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305941 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers